Aytu BioPharma Inc. (NASDAQ:AYTU) Given Consensus Recommendation of “Hold” by Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have received a consensus recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $9.3333.

Several analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Ascendiant Capital Markets increased their target price on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Finally, Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Monday, November 24th.

Aytu BioPharma Price Performance

Shares of NASDAQ AYTU opened at $2.62 on Thursday. The firm has a market cap of $26.70 million, a PE ratio of -0.86 and a beta of 0.32. Aytu BioPharma has a fifty-two week low of $0.95 and a fifty-two week high of $3.07. The business has a 50 day moving average price of $2.46 and a two-hundred day moving average price of $2.33. The company has a quick ratio of 1.08, a current ratio of 1.23 and a debt-to-equity ratio of 0.45.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%. The firm had revenue of $13.89 million for the quarter, compared to analyst estimates of $17.92 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. AWM Investment Company Inc. acquired a new stake in Aytu BioPharma in the 2nd quarter worth approximately $1,351,000. Stonepine Capital Management LLC lifted its stake in shares of Aytu BioPharma by 75.3% in the second quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock worth $1,772,000 after buying an additional 348,955 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Aytu BioPharma during the 3rd quarter worth $117,000. FNY Investment Advisers LLC bought a new stake in shares of Aytu BioPharma during the 2nd quarter worth $78,000. Finally, Two Sigma Investments LP grew its stake in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after buying an additional 33,701 shares during the last quarter. 33.49% of the stock is owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.